Abstracts tagged "Osteoarthritis"

Abstract Number: 1946 • ACR Convergence 2024
Shaping the Future of the National Musculoskeletal (MSK) Triage Initiative: Exploring the Impact of a Hybrid Model (Virtual and Face to Face) of MSK Triage
Julie Sugrue, Scott Murphy, Mark Kingston, paula Wallace, Catriona O'Dwyer, colum Moloney, Olivia McKenna, Finbarr Condon and Sean McKenna, Health Service Executive, Limerick, Limerick, Ireland
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) are the leading contributor of disability worldwide (de Thurah et al 2022). The National Musculoskeletal (MSK) Triage Initiative, ensures…
Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Ignacio Rego-Perez¹, Alejandro Duran-Sotuela², Jorge Vazquez-Garcia², Cristina Ruiz-Romero³, Valentina Calamia², Carlota Fraga-Seijas⁴, Vanesa Balboa-Barreiro⁵, Sara Relaño², María C. De Andrés², Lucia Lourido², Rocio Paz-Gonzalez², Patricia Quaranta², Patricia Fernández-Puente², Nicola Veronese⁶, Natividad Oreiro⁷ and francisco J Blanco⁸, ¹Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, ³INIBIC - CHUAC, A Coruña, Spain, ⁴INIBIC, A Coruña, Spain, ⁵Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁶Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, ⁷CHUAC, La Coruna, Galicia, Spain, ⁸INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…
Abstract Number: 2158 • ACR Convergence 2024
An MVPA Is MVPA Is MVPA, or Is It? Impact of the Definition of Moderate to Vigorous Physical Activity (MVPA) on Its Amount in Persons with Advanced Knee Osteoarthritis
Samantha Chin¹, Jamie Collins¹, Jeffrey Katz², Dorothy Dunlop³, Lauren Mitchell¹, Rowland Chang⁴, Khara James¹, Christine Pellegrini⁵, Jason Kim⁶, Katharine Fox¹, Anne Holleman¹ and Elena Losina¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Northwestern University, New Haven, CT, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵University of South Carolina, Columbia, SC, ⁶Arthritis Foundation, Atlanta, GA
Background/Purpose: ActiGraph is a gold standard for MVPA assessment with several counts per minute (CPM) validated thresholds proposed to measure MVPA. Historically, these thresholds have…
Abstract Number: 0031 • ACR Convergence 2024
Beyond Pain and Inflammation: Intra-articular Liraglutide’s Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone
Coralie Meurot¹, Celine Martin¹, Margot Vieubled¹, Jerome Breton¹, Indira Toillon², Revital Rattenbach³ and Francis Berenbaum², ¹4Moving Biotech, lille, France, ²Sorbonne University, Paris, France, ³4Moving Biotech, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease that causes chronic pain and limited mobility. Patients mainly have access to therapies aimed at reducing inflammation…
Abstract Number: 0863 • ACR Convergence 2024
The Development of Future Radiographic Knee Osteoarthritis Can Be Predicted by Peripheral Blood Epigenetic Models
Cindy Miranda¹, Nicholas Hannebutt², Gabby dyson³, Montana Barrett⁴, Aleksander Szymczak³ and Matlock Jeffries³, ¹Oklahoma Medical Research Foundation, Yukon, OK, ²Oklahoma Medical Research Foundation, Spencer, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Oklahoma, Cement, OK
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 1185 • ACR Convergence 2024
Walking Is Associated with Less Knee Pain: A Cross-sectional Study from the Osteoarthritis Initiative
Sydney Tran¹, Jeffrey Driban², Timothy McAlindon³, Andrea Kriska⁴, Bonny Rockette-Wagner⁴, Charles Eaton⁵, Marc Hochberg⁶, Kent Kwoh⁷, Michael Nevitt⁸ and Grace Lo⁹, ¹Baylor College of Medicine, Houston, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Chan Medical School, Worcester, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Warren Alpert Medical School of Brown University, Providence, RI, ⁶University of Maryland School of Medicine, Cambridge, MD, ⁷University of Arizona, Tucson, AZ, ⁸University of California, San Francisco, San Francisco, CA, ⁹Baylor College of Medicine / MEDVAMC, Houston, TX
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, with the knee being the most common joint involved. Exercise is a leading non-pharmacological treatment…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1442 • ACR Convergence 2024
Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort
Laura Pina Vegas¹, Floris van Gaalen², Miranda van Lunteren³, Damien Loeuille⁴, Caroline Morizot⁵, Esther Newsum⁶, Pascal Claudepierre⁷, Alain SARAUX⁸, Antoine Feydy⁹, Monique Reijnierse¹, Desiree van der Heijde¹⁰ and Sofia Ramiro¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Zuid-Holland, Netherlands, ³Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁴Phd, Nancy Vandoeuvre, Lorraine, France, ⁵Nancy University hospital, Nancy, France, ⁶Nij Smellinghe, Drachten, Netherlands, ⁷CHU Henri Mondor, AP-HP/EpiDermE, UPEC, Créteil, France, ⁸CHU Brest, Brest, France, ⁹CHU Cochin, AP-HP, Paris, France, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Spinal degenerative lesions (DLs) are commonly seen/reported in radiographs and MRI in axSpA. However, the relationship between the different DLs over time has not…
Abstract Number: 1947 • ACR Convergence 2024
Optimizing Osteoarthritis Care Through Clinical and Community Partnership: Results of an Exploratory Trial
Kelli Allen¹, Liubov Arbeeva², Leigh Callahan³, Katherine Combs⁴, Tamara Godfrey⁵, Yvonne Golightly⁶, Derek Hales⁵, Carla Hill⁷, Katie Huffman⁸, Amanda Nelson⁵, Jennifer Rees⁵ and Todd Schwartz⁹, ¹University of North Carolina, Durham, NC, ²University of North Carolina, Chapel Hill, Carrboro, NC, ³University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ⁴YMCA of the Triangle, Raleigh, NC, ⁵University of North Carolina at Chapel HIll, Chapel Hill, NC, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UNC Health, Raleigh, NC, ⁸UNC Thurston Arthritis Research Center, Chapel Hill, NC, ⁹University of North Carolina-Chapel Hill, Chapel Hill, NC
Background/Purpose: Many studies have documented gaps in quality of care for knee and hip osteoarthritis (OA), particularly with respect to lifestyle (e.g., weight management, exercise)…
Abstract Number: 2097 • ACR Convergence 2024
Application of Machine Learning Methods to Predict the Risk of Rapid Pain Progression in Patients with Knee OA. Study Using Patients from the OAI and PROCOAC
Ignacio Rego-Perez¹, Isabel Rodriguez-Valle², Juan Fernández-Tajes², Vanesa Balboa-Barreiro³, Carlota Fraga-Seijas², María del carmen de andres², Valentina Calamia², Patricia Fernández-Puente⁴, Nicola Veronese⁵, Cristina Ruiz-Romero⁶, Natividad Oreiro⁷ and francisco J Blanco⁸, ¹Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña UDC. As XUbias, 15006. A Coruña, España, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, ⁵Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, ⁶INIBIC - CHUAC, A Coruña, Spain, ⁷CHUAC, La Coruna, Galicia, Spain, ⁸INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: There is a need to design models based on machine learning that are capable of predicting the risk of rapid pain progression of knee…
Abstract Number: 2271 • ACR Convergence 2024
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
Jennifer Lee¹ and Ji Hyeon Ju², ¹seoul st mary's hospital, Seoul, South Korea, ²Seoul St MAry's hospital, Seoul, Republic of Korea
Background/Purpose: To assess the impact of a single intra-articular (IA) injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with knee osteoarthritis (OA).Methods: This…
Abstract Number: L04 • ACR Convergence 2023
EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis
James Helliwell¹, Amanda Malone¹, Mark Kowalski², Asger Reinstrup Bihlet³, Claire Miller⁴, Alejandro Castillo Mondragon⁵, Yanqi Li⁶, Christine Dobek⁷, Vik Peck¹, Mike Wilmink⁸ and Lee Simon⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²Eupraxia Pharmaceuticals, Winchester, VA, ³NBCD A/S, Soeborg, Denmark, ⁴NBCD A/S, Copenhagen, Denmark, ⁵NBCD, Copenhagen, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷Eupraxia Pharmaceuticals, Edmonton, AB, Canada, ⁸OrthoArizona, Phoenix, AZ, ⁹SDG LLC, Cambridge, MA
Background/Purpose: EP-104IAR is being developed to treat OA symptoms. Previous results from non-clinical studies evaluating local joint safety in beagle dogs, in contrast to other…
Abstract Number: L05 • ACR Convergence 2023
DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis
Guoqi Cai¹, Graeme Jones², Flavia Cicuttini³, Anita Wluka³, Yuanyuan Wang³, Catherine Hill⁴, Helen Keen⁵, Benny Antony², barbara de Graaff², Michael Thompson², Tania Winzenberg², Kathy Buttigieg², Petr Otahal² and Dawn Aitken², ¹School of Public Health, Anhui Medical University, Hefei, China, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Monash University, Melbourne, Australia, ⁴The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁵Fiona Stanley Hospital, Murdoch, Australia
Background/Purpose: There is an unmet need for treatments of knee OA. Diacerein is recommended for alleviating pain in OA patients for its anti-inflammatory effect by…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0319 • ACR Convergence 2023
Knee Flexion Contracture Was Associated with Articular Cartilage Loss in the Central Region but Cartilage Preservation in the Posterior Region of the Tibia: Data from the Osteoarthritis Initiative
Mark Campbell¹, Odette Laneuville² and Guy Trudel³, ¹Elisabeth Bruyere Hospital, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: A knee flexion contracture (FC), present in ~⅓ of patients with knee OA1, is the inability to fully extend the knee2, 3. Having a…

« Previous Page
1
…
7
8
9
10
11
…
63
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.